Shots:

• Biomica collaborated with Weizmann Institute of Science to develop a selective treatment against antibiotic-resistant strains of Staphylococcus aureus infection- targeting a specific microbe while maintaining the microbiome of the patients' gut.
• Biomica has in-licensed IP rights of Prof. Ada E. Yonath’s work and discoveries in the high-resolution crystal structure- allowing a high degree of specificity with Biomica's computational technology- enabling the development of selective- narrow-spectrum antibiotics
• The collaboration will put Prof. Yonath's achievements into practice- to resolve a substantial- unmet clinical need- by developing a highly selective solution to the resistance of Staphylococcus aureus

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Linkedin